Pharming Group NV (PHAR)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $891.80M
Last updated: Nov 17, 2026 at 11:03 AM ET
Pharming Group NV (PHAR) Stock Forecast
Analysts expect Pharming Group NV (PHAR) to earn $0.26 per share in the fiscal year ending Dec 31, 2026, on revenue of $387.34M. Of 4 analysts, 4 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 1 estimate for the fiscal year ending Dec 31, 2026 was revised up and 0 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 4 ratings average 2.00, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 0 | 0.0% |
| Buy | 4 | 100.0% |
| Hold | 0 | 0.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 4
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus falls 30.8% and revenue estimates rise 9.0%.
- Fiscal year ending Dec 31, 2026
- $0.26
- EPS consensus, revenue $387.34M
- Fiscal year ending Dec 31, 2027
- $0.18
- EPS consensus, revenue $422.02M
- Fiscal year ending Dec 31, 2028
- $0.36
- EPS consensus, revenue $428.40M
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $0.26 | $0.04 to $0.48 | 2 | $387.34M | $381.40M to $394.90M | 5 |
| Dec 31, 2027 | $0.18 | $0.04 to $0.32 | 2 | $422.02M | $407.80M to $451.99M | 5 |
| Dec 31, 2028 | $0.36 | $0.34 to $0.39 | 1 | $428.40M | $409.31M to $459.47M | 1 |
Quarterly Estimates
The EPS consensus falls from $0.02 for the quarter ending Dec 31, 2026 to -$0.01 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $0.02 | $0.02 to $0.03 | 5 | $116.62M | $110.96M to $118.88M | 5 |
| Mar 31, 2027 | -$0.01 | -$0.01 to -$0.01 | 1 | $77.00M | $77.00M to $77.00M | 1 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 1 upward and 3 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 1 | 0 |
| Fiscal year ending Dec 31, 2027 | 0 | 2 |
| Quarter ending Mar 31, 2027 | 0 | 1 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has risen 13.0% from $0.23.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | $0.26 | $0.61 | $0.46 | $0.46 | $0.23 | +12.9% |
| Fiscal year ending Dec 31, 2027 | $0.18 | $0.07 | $0.31 | $0.31 | $0.07 | +174.8% |
Frequently Asked Questions About PHAR
What is the PHAR stock forecast?
Consensus analyst estimates put Pharming Group NV's EPS at $0.26 for the fiscal year ending Dec 31, 2026, on revenue of $387.34M. The consensus rating from 4 analysts is Buy.
How do analysts rate PHAR stock?
Of 4 analysts covering Pharming Group NV, 0 rate it Strong Buy, 4 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from PHAR next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $0.26, with estimates from $0.04 to $0.48 from 2 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $0.18, with estimates from $0.04 to $0.32 from 2 analysts.
What revenue do analysts expect from Pharming Group NV next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $387.34M, with estimates from $381.40M to $394.90M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $422.02M, with estimates from $407.80M to $451.99M.
How many analysts cover PHAR?
4 analysts rate Pharming Group NV stock, and 2 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
PHAR pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors